Peter Kleinhenz, MBA
Managing Director Venture Group CID Capital
Peter Kleinhenz is a Venture Partner with Fletcher Spaght Ventures and a Managing Director of CID Equity, Inc. He has been actively involved in technology-based businesses as an entrepreneur, consultant, and investor for over 28 years and in the life sciences sector for over 25 years. For the past 15 years, he has been a venture capitalist focusing on investments in medical devices, diagnostics, therapeutics, and healthcare services companies. He joined Fletcher Spaght Ventures in 2009 and CID Equity, Inc. in 2001.
His has served, in board or advisory roles in over 15 companies including: AxioMed Spine Corporation, Surgiquest, Inc. (acquired by ConMed, Inc.), Cayenne Medical, Inc. (acquired by Zimmer Biomet), QIS, Inc., (sold to Abeam Consulting), Renal Solutions, Inc. (acquired by Fresenius Medical Care, AG), EKOS Corporation (acquired by BTG International), Red Path Integrated Pathology, Inc., (acquired by PDI, Inc.), Celleration, Inc. ( acquired by Alliqua Biomedical, Inc.),MedVantx, Inc. and Waterlink ( NYSE: WLK). Currently he serves as Board Chairman of Swift Biosciences, Inc. and as an advisor to Gravity Diagnostics, LLC.
Prior to joining CID Capital in 2001, Peter served as Vice President of Commercialization-Life Sciences for Battelle Memorial Institute working in medical devices, pharmaceutical products and toxicology sectors and as a consultant to The Cleveland Clinic Foundation, Battelle, and a variety of life science start-ups, assisting in developing business plans and raising seed and venture capital. He was CEO of Progenics, Inc., which developed and manufactured medical products and industrial controls, which he sold to FITCH, Inc. in 1997. He was a member of the founding management team of Neoprobe Corporation a biotech and medical device company focused on cancer diagnostics and therapeutics. At Neoprobe he served in a variety of senior executive positions including CFO, Vice President of Manufacturing, and Vice President of Product and Market Planning. Prior to this he was an Investment Analyst with the Thomas Edison Program, Ohio Department of Development where he focused on pre seed and seed stage company financings.
Peter has been a member of the Board and Executive Committee of BioOhio since 1991. He is also a founding member and Board member of the MidAmerica Health Investment Network and is the founder and Chairman of the MHIN’s annual MidAmerica Healthcare Investment Forum.Peter received an MBA from Case Western Reserve University, a bachelor’s degree from Loyola University of Chicago, and is a Certified Public Accountant licensed (inactive status) in Ohio.
End of main page content.